Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
about
Preclinical and clinical development of DNA vaccines for prostate cancer.DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responsesImmunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells.Cancer/testis antigens and urological malignanciesVaccination using peptides spanning the SYT-SSX tumor-specific translocationGeneration of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.DNA Vaccines for Prostate Cancer.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccinesNew targets for the immunotherapy of colon cancer-does reactive disease hold the answer?SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine ImmunizationEBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.Tumor-associated antigens for specific immunotherapy of prostate cancerVaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.DNA vaccines for prostate cancer.Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.[Expression and Clinical Significance of MAGE-C2 in Lung Adenocarcinoma].
P2860
Q33740811-13DB121C-6D68-49DE-9FC9-9F29DA4917F3Q34127323-D951F7DE-3153-4B98-AA26-971BDACD1D13Q34522301-BF7B9EC9-7427-4A8C-B898-78746D284F39Q35161225-BCEF7814-42D0-4CD1-B1AF-48C17ABB1AD8Q36337004-833B6D07-C95A-4B2D-938C-4354F3987336Q36565705-17FB42BA-5BFE-49DB-A03E-384AB79B14D7Q37135201-612B104F-67E9-49BB-AF6F-2D847E7D9743Q37604481-F9DBAB46-7BFF-4B76-865B-AB679248D563Q37703163-5D611AC5-E58A-432C-9365-AA82B6A1806CQ37708724-16564429-E43C-4B35-8E70-2335FB5A71B1Q38089480-3AD6AB8B-BC6E-4923-A79B-D8299AAEB86DQ38856316-89388ABD-D158-45D9-AE00-116C4BA6D235Q38867768-8249A32D-9A5E-4F27-AA36-9556660D2A3FQ39160149-BF012D88-4011-472F-B8C9-8D28DA382055Q39181825-2C7A3199-8D83-423F-8679-07482C3FFDD6Q41977894-29CED2A2-E7C8-4BEC-B96C-A0D05C970AF6Q50222492-33277ED0-1360-4631-A7CC-FCEC45FBE883Q51142505-DC52AF57-9046-4871-8BF8-A3DA136C5838Q55364522-560E8D68-BA0D-4A60-927B-8B51CDD2F8A8Q55447676-EAF57910-8DB5-4339-B7D7-B979E17D91EB
P2860
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Vaccines targeting the cancer- ...... pe-specific cytolytic T cells.
@ast
Vaccines targeting the cancer- ...... pe-specific cytolytic T cells.
@en
type
label
Vaccines targeting the cancer- ...... pe-specific cytolytic T cells.
@ast
Vaccines targeting the cancer- ...... pe-specific cytolytic T cells.
@en
prefLabel
Vaccines targeting the cancer- ...... pe-specific cytolytic T cells.
@ast
Vaccines targeting the cancer- ...... pe-specific cytolytic T cells.
@en
P2860
P1476
Vaccines targeting the cancer- ...... ope-specific cytolytic T cells
@en
P2093
Heath A Smith
P2860
P304
P356
10.1097/CJI.0B013E31822B5B1D
P577
2011-10-01T00:00:00Z